Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-01-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2077-0383/4/2/243 |
id |
doaj-08cfdce4ae524ec8b2bd5cfab3db86bb |
---|---|
record_format |
Article |
spelling |
doaj-08cfdce4ae524ec8b2bd5cfab3db86bb2020-11-25T01:02:10ZengMDPI AGJournal of Clinical Medicine2077-03832015-01-014224325910.3390/jcm4020243jcm4020243Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement TherapyIsart Roca0Jordi Requena1Michael J. Edel2Ana Belén Alvarez-Palomo3Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, Barcelona, SpainControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, Barcelona, SpainControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, Barcelona, SpainControl of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036, Barcelona, SpainThe use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle since they allow allogenic transplantation, can be produced in large quantities, and, as compared to adult myoblasts, present more embryonic-like features and more proliferative capacity in vitro, which indicates a potential for more self-renewal and regenerative capacity in vivo. Different approaches have been described to make myogenic progenitors either by gene overexpression or by directed differentiation through culture conditions, and several myopathies have already been modeled using iPSC-MP. However, even though results in animal models have shown improvement from previous work with isolated adult myoblasts, major challenges regarding host response have to be addressed and clinically relevant transplantation protocols are lacking. Despite these challenges we are closer than we think to bringing iPSC-MP towards clinical use for treating human muscle disease and sporting injuries.http://www.mdpi.com/2077-0383/4/2/243induced pluripotent stem cellsskeletal musclemuscular dystrophymyogenic progenitorsstem cell therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Isart Roca Jordi Requena Michael J. Edel Ana Belén Alvarez-Palomo |
spellingShingle |
Isart Roca Jordi Requena Michael J. Edel Ana Belén Alvarez-Palomo Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy Journal of Clinical Medicine induced pluripotent stem cells skeletal muscle muscular dystrophy myogenic progenitors stem cell therapy |
author_facet |
Isart Roca Jordi Requena Michael J. Edel Ana Belén Alvarez-Palomo |
author_sort |
Isart Roca |
title |
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy |
title_short |
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy |
title_full |
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy |
title_fullStr |
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy |
title_full_unstemmed |
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy |
title_sort |
myogenic precursors from ips cells for skeletal muscle cell replacement therapy |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2015-01-01 |
description |
The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle since they allow allogenic transplantation, can be produced in large quantities, and, as compared to adult myoblasts, present more embryonic-like features and more proliferative capacity in vitro, which indicates a potential for more self-renewal and regenerative capacity in vivo. Different approaches have been described to make myogenic progenitors either by gene overexpression or by directed differentiation through culture conditions, and several myopathies have already been modeled using iPSC-MP. However, even though results in animal models have shown improvement from previous work with isolated adult myoblasts, major challenges regarding host response have to be addressed and clinically relevant transplantation protocols are lacking. Despite these challenges we are closer than we think to bringing iPSC-MP towards clinical use for treating human muscle disease and sporting injuries. |
topic |
induced pluripotent stem cells skeletal muscle muscular dystrophy myogenic progenitors stem cell therapy |
url |
http://www.mdpi.com/2077-0383/4/2/243 |
work_keys_str_mv |
AT isartroca myogenicprecursorsfromipscellsforskeletalmusclecellreplacementtherapy AT jordirequena myogenicprecursorsfromipscellsforskeletalmusclecellreplacementtherapy AT michaeljedel myogenicprecursorsfromipscellsforskeletalmusclecellreplacementtherapy AT anabelenalvarezpalomo myogenicprecursorsfromipscellsforskeletalmusclecellreplacementtherapy |
_version_ |
1725206302232150016 |